Negative in Ames, human lymphocyte clastogenicity and rat micronucleus assays
“Mavacamten was not genotoxic in a bacterial reverse mutation test (Ames test), a human in vitro lymphocyte clastogenicity assay, or a rat in vivo micronucleus assay.”
6-month rasH2 mouse and 2-year rat: no evidence of carcinogenicity
“There was no evidence of carcinogenicity seen in a 6-month rasH2 transgenic mouse study at mavacamten doses of up to 2.0 mg/kg/day in males and 3.0 mg/kg/day in females, or in a 2-year rat study at mavacamten doses up to 0.6 mg/kg/day.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Teratogenic in rat and rabbit EFD; in rats post-implantation loss, situs inversus and skeletal malformations
“Mavacamten was shown to be teratogenic in both rats and rabbits in embryo-fetal developmental studies. In rats, mavacamten increased post-implantation loss, lowered mean fetal body weight, slightly reduced fetal skeletal ossification, induced heart malformations (total situs inversus), and increased the incidence of skeletal malformations relative to control.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
No hERG or action-potential effects in vitro; low proarrhythmic risk
“In vitro and in silico electrophysiological data indicate low torsadogenic/proarrhythmogenic risk with mavacamten, as shown by the lack of an effect on hERG channel or any action potential parameters.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Genotox: Ames
Negative up to 5000 µg/plate
“Mavacamten gave negative results in the Ames test up to the limit concentration of 5000 µg/plate and in the in vitro micronucleus assay in human lymphocytes, tested up to cytotoxic concentrations, both with and without metabolic activation.”
In vitro micronucleus in human lymphocytes: negative
“Mavacamten gave negative results in the Ames test up to the limit concentration of 5000 µg/plate and in the in vitro micronucleus assay in human lymphocytes, tested up to cytotoxic concentrations, both with and without metabolic activation.”
6-month rasH2 transgenic mouse and 2-year rat: no evidence of carcinogenicity
“There was no evidence of carcinogenicity seen in a 6-month rasH2 transgenic mouse study at mavacamten doses of up to 2.0 mg/kg/day in males and 3.0 mg/kg/day in females, or in a 2-year rat study at mavacamten doses up to 0.6 mg/kg/day.”
26-week rasH2 mouse completed; 2-year rat ongoing at approval, to be completed post-approval
“The Division has agreed the 2-year rat carcinogenicity study can be completed post-approval and the study is currently ongoing.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
hERG / QT
Minimal hERG inhibition: 5% at 10 µM and 9.6% at 60 µM
“Minimal but statistically significant increased hERG inhibition of 5% and 9.6% in HEK293 cells was noted at 10µM and 60µM, respectively, compared to controls (1%).”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative